8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Elevance Health, Inc. (ELV)

Elevance Health ($ELV) announced Feb 26, 2026 that Peter D.

Filed with the SEC on · Summarized by InvestorsBot

Elevance Health ($ELV) announced Feb 26, 2026 that Peter D. Haytaian will transition from EVP & President of Carelon effective May 4, 2026 to devote more time to family. Press release filed as Exhibit 99.1. 🏥 #Leadership #Healthcare

Haytaian will serve as Special Advisor through Dec 31, 2026 to ensure an orderly leadership transition and continuity across Carelon’s operations and client/partner relationships; decision not due to any disagreement. $ELV 🔁 #CorporateGovernance #Carelon

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Elevance Health, Inc.

Elevance Health ($ELV) reaffirms FY2026 adjusted shareholders’ earnings ≥ $25.50/share and 2026 benefit…

8-K · March 10, 2026

Feb 27, 2026: CMS notified Elevance Health ($ELV) of intent to impose intermediate sanctions — suspend…

8-K · March 2, 2026

Elevance Health ($ELV) filed an 8‑K on Feb 26, 2026 furnishing a press release (Exhibit 99.1) and the…

8-K · February 26, 2026

Elevance Health ($ELV) reaffirms FY2026 EPS guidance: ≥ $22.30 diluted (includes ~ $3.20 of net…

8-K · February 26, 2026

Elevance Health ($ELV) filed an 8‑K on Jan 28, 2026 furnishing a press release (Exhibit 99.1) with…

8-K · January 28, 2026

Elevance Health ($ELV) on Jan 28, 2026 issued a press release reporting Q4 & full‑year 2025 financial…

8-K · January 28, 2026